Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc. has successfully completed the first tranche of its Non-Brokered Private Placement, raising $775,000 CAD through the issuance of over 3.5 million units. Each unit, priced at $0.22 CAD, comprises a common share and a warrant, with the latter allowing the purchase of an additional share at $0.30 CAD within five years. The company aims to allocate the proceeds towards advancing its Phase II clinical study for Bladder Cancer, R&D of its Rutherrin® compound, and for general corporate purposes.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
